Psychiatrist and principal investigator. Two decades of careful science for the people the usual treatments have failed — from autism genetics to Phase 3 psychedelic trials — built on the conviction that rigor and compassion are the same discipline.
Board-certified psychiatrist PI with 230+ trials across MDD, TRD, GAD, PTSD, bipolar, schizophrenia, eating disorders and pediatric indications. DEA Schedule I researcher registration (five drug codes). Site-PI on Phase 3 programs from MindMed, Compass, Cybin, Transcend, Reunion and AbbVie.
See the active portfolio →First author on the 2025 JAMA MM120 trial; co-author on the 2023 JAMA psilocybin trial and the Ogden syndrome discovery. Open to co-authorship, safety-monitoring roles and pragmatic study design.
Read the publications →Board certified since 2010, medical director of an eating-disorder center for nearly a decade, principal investigator on more than 230 trials. Everything here is listed so it can be checked.
Read the CV →Schedule I is the most restricted tier of the U.S. Controlled Substances Act — drugs the DEA classes as having no accepted medical use. A physician cannot simply prescribe or order them; a separate DEA researcher registration is required for each compound, tied to specific protocols, with vault-grade storage, DEA inspection and reconciled accountability for every milligram. Reid holds an active DEA Researcher (Schedule I) registration at Inner Space Research covering five drug codes — the compounds below.
The first adequately powered randomized trial of LSD for an anxiety disorder; a single dose, no adjunctive psychotherapy, durable dose-dependent effect.
Publications →Co-author on the multicenter Usona trial that set the evidentiary bar for psilocybin in major depression.
Publications →Phase 3 psychedelic and novel-mechanism programs: MindMed, Compass, Cybin, Transcend, Reunion, AbbVie, Neurocrine, Janssen.
Now at ISR →Built one of the country's largest ketamine-assisted psychotherapy programs at Cedar Psychiatry, Novamind and Numinus; published outcomes, safety and cost-effectiveness.
Talks →Plus first case series of group ketamine-assisted psychotherapy in residential eating-disorder treatment, and the SPANYA safety committee at UCSF.
Trials →Genome-wide CNV study of ADHD, and VAAST identification of the NAA10 variant behind a lethal X-linked syndrome in Utah families.
Genetics papers →Co-founded Cedar Psychiatry and Cedar Clinical Research; grew into Novamind and Numinus, where he served as CMO and CCO.
Experience →More than 150 talks, lectures, panels, podcasts and press features, from Smithsonian and Forbes to the Psychiatric Times cover.
Talks →Additional trials, by sponsor protocol number (2012–2018). Principal Investigator: AstraZeneca D3032C00001 · ELAN ELND005-BPD-201 · Forest MEM-MD-68, MEM-MD-69, MEM-MD-91, RGH-MD-21, RGH-MD-075 · Janssen KET IVTRD 2002, R092670-PSY-3012 · Merck Sharp & Dohme MK5896, MK5892, P05898, P06107 · Novartis 2301, 2401 · Otsuka 31-10-252, 31-10-272, 31-12-274, 31-12-291, 31-12-294, 31-12-297 · Shionogi 1326V95235 · Sunovion 302 · Takeda Lu AA2104-202 · Theravance 0085 Sub-Investigator: Abbott Laboratories M11-733 · Alkermes ALK3831-302 · Amgen AMG334 20120178, 333 20130101, 333 20130102 · AstraZeneca D4750C00001 · Bristol-Myers Squibb AI444-046 · Biogen 103NS2011 · Cervel CN-CFS-TRMD-2 · Collegium CP-OXYDET 08, CP-OXYDET 21, CP-OXYDET 24 · Corcept C-1073-14 · Cubist 5946-CIC-12-04, 5945-SOIC-12-005 · ENDO EN3409-204 · Eli Lilly and Company I40-MC-BACC, I40-WE-BACX, H8MC-LZAX, AACC · IDENIX IDX-03YF · Inspirion M-ARER-003 · Janssen R381 333-PAI-2005 · Lundbeck 15352A · Merck Sharp & Dohme MK-7622 · Naurex GLYX-13-C-203, NRX1074-C-201 · Orexo OX219-006, OX219-007, OX219-008 · Pfizer A0081279 · Purdue VND2020 · Roche WN25308, WN25305, WN25203, BP28865, BP25712 · Sucampo SCMP-0211-301 · Taisho TS111-US101 · Takeda TOMM_301 · TauRx TRx237-005, TRx237-007 · Teva TV1308-COA-201, T-PIN-001, C33237-3104, C33237-3103 · Theravance 0092 · Trevena CP130-1003 · US WorldMeds USWM-LX1-1005-2, USWM-LX-1006, USWM-LX1-3003-1
Ongoing: supervises and trains sub-investigators, study physicians, and clinical raters in Good Clinical Practice, protocol conduct, and rating-scale reliability at Inner Space Research.
Has administered standardized psychiatric rating scales in regulated clinical trials since 2010 (residency years excluded), with more than 50 administrations of the CGI-S, C-SSRS, and BPRS in the past year alone. Recent rater training and certification through Signant Health, Worldwide Clinical Trials, and the Columbia Lighthouse Project (C-SSRS).
Every format is built from the same data as the rest of the site, so it is never out of date. Copy as text or Markdown, or print to PDF.